Johnson & Johnson (NYSE:JNJ) Shares Purchased by Fernwood Investment Management LLC

Posted by on Jul 29th, 2023

Fernwood Investment Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 8.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,833 shares of the company’s stock after acquiring an additional 1,608 shares during the quarter. Johnson & Johnson accounts for 1.3% of Fernwood Investment Management LLC’s holdings, making the stock its 19th largest position. Fernwood Investment Management LLC’s holdings in Johnson & Johnson were worth $3,384,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. GW&K Investment Management LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $35,000. Dark Forest Capital Management LP increased its position in shares of Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after buying an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $42,000. Kepos Capital LP purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $45,000. Finally, VitalStone Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $52,000. 67.57% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on JNJ shares. Raymond James boosted their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a research report on Monday, July 24th. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Barclays boosted their price target on Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Monday, July 24th. Stifel Nicolaus boosted their price target on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Finally, Atlantic Securities dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $171.60.

Insider Activity

In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $174.51 on Friday. The business’s fifty day moving average price is $161.76 and its 200 day moving average price is $161.30. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The company has a market capitalization of $453.50 billion, a PE ratio of 35.33, a P/E/G ratio of 2.90 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The company had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter in the prior year, the business earned $2.59 EPS. Johnson & Johnson’s revenue was up 6.3% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.76 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.73%. Johnson & Johnson’s payout ratio is currently 96.36%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.